Table 2 Patient characteristics
From: Constraining the brachial plexus does not compromise regional control in oropharyngeal carcinoma
Characteristic | Number (%) |
|---|---|
Sex | |
Male | 39 (92.9%) |
Female | 3 (7.1%) |
Age | |
≤55 | 12 (28.6%) |
>55 | 30 (71.4%) |
Race | |
White | 37 (88.1%) |
Not white | 5 (11.9%) |
KPS | |
90-100 | 34 (81.0%) |
60-80 | 8 (19.0%) |
Primary site | |
Tonsil | 13 (31.0%) |
Base of tongue | 29 (69.0%) |
Pharyngeal wall | 0 (0%) |
Soft palate | 0 (0%) |
T stage | |
T1 | 7 (16.7%) |
T2 | 21 (50.0%) |
T3 | 6 (14.3%) |
T4 | 8 (19.0%) |
N stage | |
N0 | 0 (0%) |
N1 | 2 (4.8%) |
N2 | 34 (81.0%) |
N3 | 6 (14.3%) |
AJCC Stage | |
I | 0 (0%) |
II | 0 (0%) |
III | 1 (2.4%) |
IV | 41 (97.6%) |
Tobacco exposure | |
Never smoked | 8 (19.0%) |
Former smoker | 26 (61.9%) |
Current smoker | 7 (16.7%) |
Number of pack years | |
Median (range) | 8 (0–84) |
Neck dissection before radiation | |
No | 42 (100%) |
Yes | 0 (0%) |
Chemotherapy | 42 (100%) |
Concurrent | 38 (90.5%) |
Cisplatin | 20 (47.6%) |
Carboplatin/5-FU | 1 (2.4%) |
Carboplatin/paclitaxel | 1 (2.4%) |
Cetuximab | 11 (26.2%) |
Cisplatin/bevacizumab | 5 (11.9%) |
Induction + concurrent | 3 (7.1%) |